Option Care Health Inc SEC Filings

Option Care Health (OPCH) filed its Q3 2025 10‑Q, reporting solid growth with stable profitability. Net revenue rose to $1,435,016,000 from $1,278,546,000, up 12.2% year over year, driven by increased acute and chronic therapy volumes. Gross profit was $272,902,000 versus $256,749,000, while operating income held at $84,507,000. Net income was $51,816,000 compared with $53,856,000, and diluted EPS was $0.32 versus $0.31.

For the first nine months, revenue reached $4,184,073,000 and net income was $149,081,000. The company closed the Intramed Plus acquisition for $117,247,000 (net of cash), adding referral sources and trademarks and increasing goodwill. It refinanced its First Lien Term Loan, cutting the rate to Term SOFR plus 1.75% and extending maturity to September 22, 2032, and added $49,600,000 of incremental debt. Cash from operations was $222,556,000; cash ended at $309,822,000. OPCH repurchased 6,805,621 shares year‑to‑date for $212,500,000, with $287,500,000 remaining under its authorization. Shares outstanding were 160,108,000 as of September 30, 2025.

Option Care Health (OPCH) furnished an update on its business by announcing it issued a press release with third quarter 2025 financial results. The press release is attached as Exhibit 99.1 to this Form 8-K. The company states the materials are furnished, not filed, which limits Exchange Act liability and incorporation by reference unless specifically noted.

The press release includes non-GAAP financial measures with reconciliations to the most comparable GAAP metrics. OPCH’s common stock trades on the Nasdaq Global Select Market under the symbol OPCH.

Option Care Health reported a Form 4 disclosing that Meenal Sethna, the company’s Chief Financial Officer, received an award of 55,067 restricted stock units in a transaction dated 10/01/2025. The units were issued at a price of $0 and are shown as directly beneficially owned at 55,067 shares following the award. The filing notes the restricted stock units "vest on the third anniversary of the grant date," and the Form 4 was signed on behalf of Ms. Sethna by an attorney-in-fact on 10/03/2025. The disclosure is a standard insider compensation award reported under Section 16 rules and contains no additional financial results, sales, or derivative transactions.

Option Care Health CFO Meenal Sethna filed an initial Form 3 under Section 16 reporting her relationship to the issuer as Chief Financial Officer and a director/officer. The filing states no securities are beneficially owned as of the event date 10/01/2025, and the form was signed on 10/03/2025.

Option Care Health entered into a Fourth Amendment to its First Lien Credit Agreement that refinances its existing term loans into a new seven-year tranche priced at Term SOFR plus 1.75%. The amendment also provides for incremental term loans totaling $49,639,386.20 at the same rate and maturity, and extends the maturity of the revolving credit commitments to the fifth anniversary of the amendment, subject to a springing maturity 91 days prior to the Unsecured Notes maturity if any Unsecured Notes remain outstanding. After the amendment, the principal amount of First Lien Term Loan indebtedness is approximately $678,000,000. The amendment was executed by the company and Bank of America, N.A., as administrative agent.

Option Care Health director Norman L. Wright purchased 3,411 shares of OPCH common stock on 09/09/2025 at a weighted average price of $29.3099 per share, with individual purchase prices ranging from $29.28 to $29.31. After the transactions, the reporting person beneficially owned 15,501 shares. The Form 4 was signed by Michael Shapiro as attorney-in-fact on 09/10/2025. No derivative securities were reported in this filing.

Pate R. Carter, a director of Option Care Health, Inc. (OPCH), reported purchasing 750 shares of the company's common stock on 08/20/2025 at a weighted average price of $27.1886 per share. After the reported purchase the filing shows the reporting person beneficially owns 41,910 shares. The transaction is coded "P" (purchase). The explanatory note states the 750 shares were bought in multiple transactions with prices ranging from $27.18 to $27.1899, and the reporter will provide detailed per-trade quantities and prices upon request. The Form 4 was signed on behalf of Mr. Carter by an attorney-in-fact.

Option Care Health director Harry M. Kraemer Jr. purchased 36,000 shares of common stock on 08/20/2025 at a weighted average price of $27.1466 per share, increasing his direct beneficial ownership to 375,390 shares. The Form 4 reports the purchases were executed in multiple transactions with individual prices ranging from $26.92 to $27.20 per share, and notes the reporting person will provide detailed allocation information upon request. The filing identifies Mr. Kraemer as a director and indicates the transaction code as "P" for purchase.

Option Care Health director Timothy P. Sullivan reported an open-market purchase of common stock on 08/21/2025. The Form 4 shows a purchase (transaction code P) of 20,000 shares at $27.51 per share, bringing his beneficial ownership to 49,229 shares, held directly. The filing was signed on behalf of Mr. Sullivan by an attorney-in-fact, Michael Shapiro.